Ensys Bioscience Completes Final Enrollment for PF614-MPAR-102

ENSC Ensysce Biosciences Inc

$0.43 +2.58%

View chart & analysis →

BIVI 0.00%

1. 1Ensys Bioscience (ENSC) has completed final patient enrollment for the PF614-MPAR-102 clinical trial
2. 2Part 3 of the second PF614-MPAR study, supported by NIDA, evaluated overdose protection profiles
3. 3The program is an oral abuse-deterrent opioid designated as a breakthrough therapy

Source ACCESSWIRE +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →